{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Progression to multiple myeloma was assessed according to International Myeloma Working Group criteria during the 1 year follow up period following treatment initiation.","groups":[{"description":"Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks","id":"OG000","title":"Denosumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis includes participants with evaluable disease progression assessment data during the 1 year follow up period.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Proportion of Participants With Progression to Multiple Myeloma","type":"SECONDARY","unitOfMeasure":"Participants"}